ADOPT-A Trial Kicks SJM Into Overdrive In Race For AF Suppression Pacing
This article was originally published in The Gray Sheet
Executive Summary
St. Jude said it expects to earn the first PMA approval of a pacing algorithm for the treatment of atrial fibrillation (AF) based on its Atrial Dynamic Overdrive Pacing Trial-A (ADOPT-A).
You may also be interested in...
FDA May Ask Circulatory Panel To Revisit AF Burden Definition, CryoCor Says
The CryoCor cardiac cryoablation system will be the first FDA-approved device for treating paroxysmal (episodic) atrial fibrillation by ablating the pulmonary vein ostia, the source of about one-third of all AF, according to San Diego developer CryoCor
FDA May Ask Circulatory Panel To Revisit AF Burden Definition, CryoCor Says
The CryoCor cardiac cryoablation system will be the first FDA-approved device for treating paroxysmal (episodic) atrial fibrillation by ablating the pulmonary vein ostia, the source of about one-third of all AF, according to San Diego developer CryoCor
AF Suppression Algorithm Approval Yields Turn-On For St. Jude Pacer Line
St. Jude Medical is confident it will earn a PMA supplement by year-end to activate its Dynamic Atrial Overdrive (DAO) atrial fibrillation suppression algorithm in patients already implanted with the Integrity AFx DR or Integrity Micro AutoCapture cardiac pacers.